KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Return on Capital Employed (2016 - 2026)

Pfizer has reported Return on Capital Employed over the past 18 years, most recently at 10.2% for Q1 2026.

  • Quarterly Return on Capital Employed fell 467.0% to 10.2% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 10.2% through Mar 2026, down 467.0% year-over-year, with the annual reading at 11.93% for FY2025, 3326.0% up from the prior year.
  • Return on Capital Employed was 10.2% for Q1 2026 at Pfizer, up from 10.29% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 37.02% in Q4 2022 and troughed at 23.16% in Q4 2023.
  • The 5-year median for Return on Capital Employed is 9.23% (2024), against an average of 1.17%.
  • Year-over-year, Return on Capital Employed surged 1419bps in 2022 and then tumbled -4594bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 37.02% in 2022, then crashed by -163bps to 23.16% in 2023, then skyrocketed by 60bps to 9.23% in 2024, then fell by -12bps to 10.29% in 2025, then rose by 1bps to 10.2% in 2026.
  • Per Business Quant, the three most recent readings for PFE's Return on Capital Employed are 10.2% (Q1 2026), 10.29% (Q4 2025), and 19.18% (Q3 2025).